Byuong Ryu, MD
NPI 1720153497 · Specialist · Syracuse, NY
Enrolled with Medicare as Practitioner - Obstetrics/Gynecology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1720153497
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Credential
- MD
- Sex
- Male
- Sole proprietor
- No
- License
- 209295 (NY)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
734 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Colorectal Cancer Screening; Fecal Occult Blood Test, Immunoassay, 1-3 SimultaneousG0328 | 144 | $15 |
| Cervical Or Vaginal Cancer Screening; Pelvic and Clinical Breast ExaminationG0101 | 136 | $37 |
| Screening 3d Breast Mammography77063 | 105 | $22 |
| Screening Mammography77067 | 105 | $85 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 105 | $86 |
| Dxa Bone Density Measurement of Hip, Pelvis, Spine77080 | 62 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 21 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Estradiol | 265 | 101 |
| Estrogens, Conjugatedbrand: Premarin | 126 | 40 |
| Estradiolbrand: Estradiol (twice Weekly) | 51 | 15 |
| Medroxyprogesterone Acetate | 48 | 16 |
| Ibandronate Sodium | 46 | 14 |
| Estradiol/Norethindrone Acetbrand: Estradiol-Norethindrone Acetat | 45 | 16 |
| Clotrimazole/Betamethasone Dipbrand: Clotrimazole-Betamethasone |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$71 across 1 record (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-11-21
- Last updated
- 2008-05-06
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.